Memory versus effector immune responses in oncolytic virotherapies

Journal of Theoretical Biology
Cicely Macnamara, R Eftimie

Abstract

The main priority when designing cancer immuno-therapies has been to seek viable biological mechanisms that lead to permanent cancer eradication or cancer control. Understanding the delicate balance between the role of effector and memory cells on eliminating cancer cells remains an elusive problem in immunology. Here we make an initial investigation into this problem with the help of a mathematical model for oncolytic virotherapy; although the model can in fact be made general enough to be applied also to other immunological problems. According to this model, we find that long-term cancer control is associated with a large number of persistent effector cells (irrespective of the initial peak in effector cell numbers). However, this large number of persistent effector cells is sustained by a relatively large number of memory cells. Moreover, the results of the mathematical model suggest that cancer control from a dormant state cannot be predicted by the size of the memory population.

References

Oct 8, 2016·Bulletin of Mathematical Biology·R EftimieDoreen A Cantrell
Sep 15, 2020·Bulletin of Mathematical Biology·Asia Wyatt, Doron Levy
Jul 23, 2019·Mathematical Medicine and Biology : a Journal of the IMA·Tyler Cassidy, Antony R Humphries

Citations

May 11, 2002·Nature Reviews. Immunology·Susan M KaechRaft Ahmed
Aug 15, 2002·British Medical Bulletin·Said DermimePeter L Stern
May 8, 2004·Seminars in Immunology·Shane Crotty, Rafi Ahmed
May 14, 2004·Journal of Virology·E John Wherry, Rafi Ahmed
Jun 24, 2004·Bulletin of Mathematical Biology·Joseph T WuLawrence M Wein
Jun 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Christopher A KlebanoffNicholas P Restifo
Jul 11, 2006·Immunological Reviews·Christopher A KlebanoffNicholas P Restifo
Jun 21, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Caroline J BreitbachJohn C Bell
Mar 5, 2008·Journal of Theoretical Biology·Z BajzerD Dingli
Jun 3, 2008·Journal of Leukocyte Biology·Michele W L TengMark J Smyth
Jan 30, 2009·Cancer Research·L R PaivaM L Martins
Sep 30, 2009·Bulletin of Mathematical Biology·Matt BieseckerZ Bajzer
Jan 21, 2010·Journal of Theoretical Biology·Natalia L Komarova, Dominik Wodarz
Apr 7, 2010·Cancer Letters·Nava Almog
Jun 17, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Byram W BridleYonghong Wan
Jan 18, 2011·International Reviews of Immunology·Himanshu KumarShizuo Akira
May 11, 2011·The Journal of Clinical Investigation·Lukas BaitschDaniel E Speiser
Jul 13, 2011·Proceedings of the National Academy of Sciences of the United States of America·Jonathan W Uhr, Klaus Pantel
Dec 21, 2011·Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics·L R PaivaS C Ferreira
May 19, 2012·Trends in Molecular Medicine·Ivana BozicMartin A Nowak
Jun 22, 2012·PLoS Computational Biology·Dominik WodarzNatalia L Komarova
Jul 4, 2012·Advances in Virology·Nanhai G ChenUlrich M Lauer
Jul 12, 2012·Nature Biotechnology·Stephen J RussellJohn C Bell
Apr 11, 2013·Current Opinion in Immunology·Leonie E PaulisCarl G Figdor
Sep 21, 2013·Nature Immunology·Thomas F GajewskiYang-Xin Fu
Feb 11, 2014·Interface Focus·Kathleen P Wilkie, Philip Hahnfeldt
Aug 29, 2014·PLoS Computational Biology·Sébastien BenzekryPhilip Hahnfeldt

Related Concepts

Tumor Cells, Uncertain Whether Benign or Malignant
Immune Response
Biochemical Pathway
Size
Immune Effector Cell
Virus Diseases
Pathogenic Organism
BLOOD GROUP--RHESUS System E Polypeptide
Virion
Permanent Nystagmus

Related Feeds

Related Papers

Orvosi hetilap
József Sinkovics, József Horváth
Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
A Sakai
British Medical Journal
G HADFIELD
© 2020 Meta ULC. All rights reserved